Balyasny Asset Management LLC Adc Therapeutics Sa Transaction History
Balyasny Asset Management LLC
- $54.8 Billion
- Q1 2024
A detailed history of Balyasny Asset Management LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Balyasny Asset Management LLC holds 23,765 shares of ADCT stock, worth $75,097. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,765Holding current value
$75,097% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ADCT
# of Institutions
43Shares Held
36MCall Options Held
156KPut Options Held
55.9K-
Redmile Group, LLC San Francisco, CA15.3MShares$48.3 Million2.7% of portfolio
-
Prosight Management, LP Dallas, TX7.05MShares$22.3 Million9.1% of portfolio
-
Morgan Stanley New York, NY2.72MShares$8.6 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.54MShares$4.87 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.27MShares$4.01 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $245M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...